Committed To Extending the Lives of Patients--

We are a strategic Contract Research Organization (CRO) running multiple clinical trials in community oncology sites throughout the US. Uniquely focused on community-based Hematology & Oncology research sites, we provide real-world experience, data and outcomes that lead to improved clinical utility of cancer therapies, improving the lives of cancer patients.

Learn More

Partner Companies

Client_Amgen-100
Client_Cephalon-100
Client_CTI-100
Client_CYTOGEN-100
Client_CytRx-100
Client_Genoptix-100
Client_Gloucester-100
Client_Janssen-100
Client_Karyopharm-100
Client_Merck-100
Client_Novartis-100
Client_Onyx-100
Client_SeattleGen-100
Client_Takeda-100
Client_Teva-100
Client_Vidacare-100
Client_Xyte-100
Client_Ziopharm-100
Clients_Bristol-100
Clients_Celgene-100
Clients_Incyte-100
Clients_OncoTracker-100
Clients_Sanofi-100
Clients_Sunesis-100

Who We Serve

WhoServe_Industry_CRO_LRG

Industry & CROs

We provide high-quality deliverables to our partners who enjoy the benefits of our proactive, personal approach. Our comprehensive, personalized service portfolio can be tailored to support preclinical research and phase 1-4 clinical trials.

Learn More
WhoServe_Sites_Invest_LRG

Sites & Investigators

Our experience in oncology makes us as a desirable partner, dedicated to our principal investigators. We help prepare and conduct the protocol for the study, monitor the safety of the study, collect and analyze data, and ultimately report all results.

Learn More
WhoServe_Patients_Care_LRG

Patients & Caregivers

Our extensive network of hospitals, community research sites and clinics increases the likelihood of finding qualified matches for your particular protocol, advancing the process markedly.

Learn More

A Comprehensive, Personalized Service Portfolio Tailored To Your Research

Capabilities_Targeted

Targeted

We are a nationally renowned and respected CRO with 15+ years experience with phase 1 – 4 clinical trials focused on hematology and oncology drug and diagnostic development for improved utilization and patient outcomes.

Capabilities_Committed

Devoted

We are committed to top community oncology research sites nationwide, enabling us to accelerate study startup, activation and patient enrollment to increase speed to results, treatment evolutions and improved patient outcomes.

Capabilities_Deliver

Deliver

ONCOtherapeutics provides strategic and appropriately focused resources and services to all of our customers. This results in efficiencies, timeliness and superior results leading to treatment innovation and optimization through publications in top peer-reviewed journals.


The Latest News

13

Ongoing Trials

55

Completed Projects

297

Publications

Focused On You For More Access & Efficiency

Committed to the highest standards of industry conduct, our reputation has been built on identifying and understanding each partner's unique demands. We are dedicated to our partners and patients, and you can be confident with our qualified and dedicated team for fairness, credibility and transparency. You can always rely on us for outstanding service, quality and cost efficiencies.

Learn More
Clinical_Trials

Active Clinical Trials

Ongoing trials and their status.

Review Now
Press_Releases

Press Releases

Our latest news.

Read Now

Leveraging A Broad Array of Experienced Community Oncology Research Sites, Design & Executions

Programs_TreatmentOpt

Cancer Treatment Optimization

Clinical trials to improve and/or expand the utility of existing cancer drugs and treatment regimens.

Tissue_Sample

Tissue Sample Collection & Outcomes

Protocols for non-interventional studies in specific tumor types across hematology and oncology.

Tissue_Sample_copy

Strategic Business Partnerships

Serve as the ‘preferred vendor’ for institutions and companies for strategy and design and conduct of clinical development programs.

Streamline Your Process To Give Patients More

Let’s discuss how our comprehensive clinical study management services can streamline the execution of your clinical trial, affecting greater cost savings and expediting the development and delivery of innovative oncology treatments.